BOSTON & MONTREAL, December 30, 2024--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company ...

Shares of ENGN stock opened at $5.96 on Monday. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The stock’s 50-day moving average is $8.13 and its two-hundred day ...

ENGN opened at $6.32 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. enGene has a fifty-two week low of $4.42 and a fifty-two week ...

BOSTON & MONTREAL, December 30, 2024--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of enGene (ENGN) with a Buy rating and $25 price target The firm says the The non-muscle invasive bladder cancer treatment landscape is ...

enGene Holdings Inc. (ENGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

enGene (ENGN) is in a strong clinical and financial position as we close the year,” said Ron Cooper, Chief Executive Officer of enGene. “With trial recruitment open across all cohorts ...

On Monday, H.C. Wainwright began coverage on Engene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a price target of $25.00. The firm's analyst highlighted the potential of enGene's gene ...

enGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Engene Holdings Inc. faces significant business risks due to its limited experience in conducting later-stage ...